AnorMED Inc. Company Profile

07:43 EST 17th December 2018 | BioPortfolio

AnorMED was founded in 1996 and listed on the TSX as “AOM” in 1999 and on the AMEX as "AOM" in 2005. To date, the Company has raised over $160 million to support its research and development programs. Over the past years AnorMED has grown to over 140 employees - the majority of which are scientists - including chemists, biochemists and biologists. Unlike many biotech companies that focus on developing therapeutic proteins and peptides or have a platform technology, AnorMED uses chemistry as its primary approach to discovering and developing new drugs. The Company has a number of core products and programs in various stages of development. MOZOBIL is a stem cell mobilizer currently in a phase III program for cancer patients undergoing stem cell transplant. In December 2004, AnorMED reached an agreement, by a Special Protocol Assessment (SPA), with the FDA on the Phase III clinical trial design, and in January 2005 initiated the Phase III trials. AMD070 is the Company's lead HIV candidate and is currently in two Phase Ib/IIa trials. One trial is being conducted in collaboration with the Adult AIDS Clinical Trials Group and the second trial, XACT, is being conducted solely by AnorMED. A Phase Ia study to evaluate AMD070’s safety in healthy volunteers has been completed. In the area of HIV, AnorMED has also developed a series of compounds that inhibit the CCR5 receptor, and the Company plans to select a lead candidate for clinical studies. The Company also has a preclinical program evaluating the potential of CXCR4 inhibitors in oncology and has established a number of significant collaborations within that evaluation. AnorMED’s goals for 2006 include establishing clinical anti-HIV activity for AMD070, selecting a new CCR5 HIV entry inhibitor for clinical studies, and completing recruitment and three month follow-up for MOZOBIL phase III studies..


#200 - 20353 64th Avenue
British Columbia
V2Y 1N5


Phone: 604.530.1057
Fax: 604.530.0976

News Articles [1 Associated News Articles listed on BioPortfolio]

X4 Pharmaceuticals Appoints Gary J. Bridger, PhD, to Board of Directors

Leader brings expertise in financing, corporate planning and R&D strategy for biotechnology companies X4 Pharmaceuticals, a clinical stage biotechnology company dev...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [2 Associated Companies listed on BioPortfolio]

AnorMed Incorporated

AnorMED Inc. is a publicly traded biopharmaceutical company dedicated to the discovery of small molecule metal complexes and metal binding drugs for the treatment of life threatening diseases. In orde...

AnorMED Inc.

AnorMED was founded in 1996 and listed on the TSX as “AOM” in 1999 and on the AMEX as "AOM" in 2005. To date, the Company has raised over $160 million to support its research and development progr...

More Information about "AnorMED Inc." on BioPortfolio

We have published hundreds of AnorMED Inc. news stories on BioPortfolio along with dozens of AnorMED Inc. Clinical Trials and PubMed Articles about AnorMED Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of AnorMED Inc. Companies in our database. You can also find out about relevant AnorMED Inc. Drugs and Medications on this site too.

Quick Search


Relevant Topic

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Corporate Database Quicklinks

Searches Linking to this Company Record